![ECOG-ACRIN logo[19516]275x75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
July 7, 2021
ECOG-ACRIN will hold its Fall 2021 Group Meeting as a face-to-face meeting for the first time in two years
July 7, 2021
Could a culturally-sensitive app help improve endocrine therapy medication adherence in Hispanic/Latina patients undergoing breast cancer treatment?
July 7, 2021
ECOG-ACRIN has established a Task Force on Advancement for Women under the leadership of Barbara Burtness, MD of Yale University
July 7, 2021
Recent ECOG-ACRIN trial updates and results
July 7, 2021
This phase II/III study is comparing the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery
July 7, 2021
This phase II study will test the effect of nivolumab plus ipilimumab, with short-course radiation, for the neoadjuvant treatment of patients with low-lying, locally advanced MSI-H/dMMR rectal cancer
July 7, 2021
The GIANT trial (EA2186) is the first randomized clinical trial to focus on vulnerable older adults with treatment-naïve metastatic pancreatic cancer who are not candidates for standard therapy
